High morbidity during treatment and residual pulmonary disability in pulmonary tuberculosis: Under-recognised phenomena

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Ralph, Anna P ^a,b   Kenangalem, Enny ^c,d   Waramori, Govert ^e   Pontororing, Gysje J ^c   Sandjaja, ^f   Tjitra, Emiliana ^f   Maguire, Graeme P ^g,h   Kelly, Paul M ^i,j   Anstey, Nicholas M ^a,b  

^a MENZIES SCHOOL OF HEALTH RESEARCH   (Australia)

^b ROYAL DARWIN HOSPITAL   (Australia)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d District Health Authority   (Indonesia)

^e Public Health and Malaria Control Department Papua   (Indonesia)

^f NATIONAL INSTITUTE OF HEALTH RESEARCH AND DEVELOPMENT   (Indonesia)

^g BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^h JAMES COOK UNIVERSITY   (Australia)

ⁱ Population Health Division   (Australia)

^j The Australian National University   (Australia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ETHAMBUTOL; PYRAZINAMIDE; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ADULT; ARTHRALGIA; ARTICLE; CONTROLLED STUDY; DISEASE DURATION; DISEASE SEVERITY; FEMALE; FORCED EXPIRATORY VOLUME; FUNCTIONAL STATUS; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INDONESIA; LUNG DISEASE; LUNG FUNCTION; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MORBIDITY; NAUSEA; PATIENT MONITORING; PRURITUS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RESIDUAL PULMONARY DISABILITY; TREATMENT OUTCOME; VOMITING; WALKING;

ADULT; ANTITUBERCULAR AGENTS; CASE-CONTROL STUDIES; DISABLED PERSONS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INDONESIA; MALE; MORBIDITY; QUALITY OF LIFE; RESPIRATORY FUNCTION TESTS; TREATMENT OUTCOME; TUBERCULOSIS, PULMONARY; YOUNG ADULT;

EID: 84896699217     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0080302     Document Type: Article

References (48)

1. Sassi F (2006) Calculating QALYs, comparing QALY and DALY calculations. Health Policy Plan 21: 402-408. doi:10.1093/heapol/czl018. PubMed: 16877455.
2. World Health Organisation (2011) Methods used to estimate the burden of disease caused by TB. Annex 1, global TUBERCULOSIS Report 2012
3. Pasipanodya JG, McNabb SJ, Hilsenrath P, Bae S, Lykens K et al. (2010) Pulmonary impairment after tuberculosis and its contribution to TB burden. BMC Public Health 10: 259. doi: 10.1186/1471-2458-10-259. PubMed: 20482835.
4. Yee D, Valiquette C, Pelletier M, Parisien I, Rocher I et al. (2003) Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. Am J Respir Crit Care Med 167: 1472-1477. doi:10.1164/rccm.200206-626OC. PubMed: 12569078. (Pubitemid 37363354)
5. Schaberg T, Rebhan K, Lode H (1996) Risk factors for side-effects of isoniazid, rifampin and pyrazinamide in patients hospitalized for pulmonary tuberculosis. Eur Respir J 9: 2026-2030. doi: 10.1183/09031936.96.09102026. PubMed: 8902462. (Pubitemid 26333539)
6. Gülbay BE, Gürkan OU, Yildiz OA, Onen ZP, Erkekol FO et al. (2006) Side effects due to primary antituberculosis drugs during the initial phase of therapy in 1149 hospitalized patients for tuberculosis. Respir Med 100: 1834-1842. doi:10.1016/j.rmed.2006.01.014. PubMed: 16517138. (Pubitemid 44283749)
7. Hnizdo E, Singh T, Churchyard G (2000) Chronic pulmonary function impairment caused by initial and recurrent pulmonary tuberculosis following treatment. Thorax 55: 32-38. doi:10.1136/thorax.55.1.32. PubMed: 10607799. (Pubitemid 30248776)
8. Maguire GP, Anstey NM, Ardian M, Waramori G, Tjitra E et al. (2009) Pulmonary tuberculosis, impaired lung function, disability and quality of life in a high-burden setting. Int J Tuberc Lung Dis 13: 1500-1506. PubMed: 19919767.
9. Menezes AM, Hallal PC, Perez-Padilla R, Jardim JR, Muiño A et al. (2007) Tuberculosis and airflow obstruction: evidence from the PLATINO study in Latin America. Eur Respir J 30: 1180-1185. doi: 10.1183/09031936.00083507. PubMed: 17804445. (Pubitemid 351194767)
10. Pasipanodya JG, Miller TL, Vecino M, Munguia G, Garmon R et al. (2007) Pulmonary impairment after tuberculosis. Chest 131: 1817-1824. doi:10.1378/chest.06-2949. PubMed: 17400690. (Pubitemid 46981640)
11. Salvi SS, Barnes PJ (2009) Chronic obstructive pulmonary disease in non-smokers. Lancet 374: 733-743. doi:10.1016/S0140-6736(09)61303-9. PubMed: 19716966.
12. Plit ML, Anderson R, Van Rensburg CE, Page-Shipp L, Blott JA et al. (1998) Influence of antimicrobial chemotherapy on spirometric parameters and pro-inflammatory indices in severe pulmonary tuberculosis. Eur Respir J 12: 351-356. doi: 10.1183/09031936.98.12020351. PubMed: 9727784. (Pubitemid 28389528)
13. Handojo T, Anstey N, Kelly P, Pain M, Kenangalem E et al. (2006) Normal spirometry, gas transfer and lung volume values in Papua. Indonesia - Southeast Asian J Trop Med Public Health 37: 571-577.
14. Pasipanodya JG, Miller TL, Vecino M, Munguia G, Bae S et al. (2007) Using the St. George respiratory questionnaire to ascertain health quality in persons with treated pulmonary tuberculosis. Chest 132: 1591-1598. doi:10.1378/chest. 07-0755. PubMed: 17890471. (Pubitemid 350156017)
15. Jones PW, Quirk FH, Baveystock CM, Littlejohns P (1992) A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire. Am Rev Respir Dis 145: 1321-1327. doi:10.1164/ajrccm/145.6.1321. PubMed: 1595997.
16. American Thoracic Society (2013) St George's Respiratory Questionnaire (SGRQ). Available: http://www.thoracic.org/assemblies/srn/questionaires/sgrq. php. Accessed 5 August 2013
17. Ralph AP, Waramori G, Pontororing GJ, Kenangalem E, Wiguna A et al. (2013) L-arginine and Vitamin D adjunctive therapies in pulmonary tuberculosis: a randomised, double-blind, placebo-controlled trial. PLOS ONE 8: e70032. doi:10.1371/journal.pone.0070032. PubMed: 23967066.
18. World Health Organisation (2002) Operational guide for the for national tuberculosis programs on the introduction and use of fixed-dose combination drugs. WHO/CDS/TB/2002.308.
19. Ardian M, Meokbun E, Siburian L, Malonda E, Waramori G et al. (2007) A public-private partnership for TB control in Timika, Papua Province. Indonesia - Int J Tuberc Lung Dis 11: 1101-1107. (Pubitemid 47605400)
20. Pontororing GJ, Kenangalem E, Lolong DB, Waramori G, Sandjaja et al. (2010) The burden and treatment of HIV in tuberculosis patients in Papua Province, Indonesia: a prospective observational study. BMC Infect Dis 10: 362. doi:10.1186/1471-2334-10-362. PubMed: 21605474.
21. Statistics Indonesia and the Ministry of Health (2006) Risk Behaviour and HIV Prevalence in Tanah Papua 2006: Results of the IBBS 2006 in Tanah Papua. Available: http://siteresources.worldbank.org/INTINDONESIA/Resources/ Publication/PapuaHIV-en.pdf. Accessed February 2009
22. Campaign for Tobacco-Free Kids. Indonesia (2010). Available: http://global.tobaccofreekids.org/en/global-epidemic/indonesia/. Accessed 20 August 2013
23. Therapeutic Goods Administration (2000) Note for guidance on Good Clinical Practice (CPMP/ICH/135/95) annotated with TGA comments. Commonwealth Department of Health and Aged Care. Available: http://www.tga.gov.au/DOCS/pdf/ euguide/ich/ich13595.pdf. Accessed 1 May 2013
24. Kesehatan Departemen Republik Indonesia (2007); Nasional Pedoman Pendenggulangan Tuberkulosis, Edisi 2, Cetakan pertama. Jakarta, Indonesia
25. World Health Organization, International Union Against Tuberculosis and Lung Disease, Royal Netherlands Tuberculosis Association. (2001) (2001) Revised international definitions in tuberculosis control. Int J Tuberc Lung Dis 5: 213-215. PubMed: 11326818.
26. Ralph AP, Ardian M, Wiguna A, Maguire GP, Becker NG et al. (2010) A simple, valid, numerical score for grading chest x-ray severity in adult smear-positive pulmonary tuberculosis. Thorax 65: 863-869. doi: 10.1136/thx.2010.136242. PubMed: 20861290.
27. Jones PW (2002) Interpreting thresholds for a clinically significant change in health status in asthma and COPD. Eur Respir J 19: 398-404. doi:10.1183/09031936.02.00063702. PubMed: 11936514.
28. American Thoracic Society (2002) ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 166: 111-117. Available online at: doi:10.1164/ajrccm.166.1.at1102. PubMed: 12091180
29. Camarri B, Eastwood PR, Cecins NM, Thompson PJ, Jenkins S (2006) Six minute walk distance in healthy subjects aged 55-75 years. Respir Med 100: 658-665. doi:10.1016/j.rmed.2005.08.003. PubMed: 16229997. (Pubitemid 43285753)
30. Stevens D, Elpern E, Sharma K, Szidon P, Ankin M et al. (1999) Comparison of hallway and treadmill six-minute walk tests. Am J Respir Crit Care Med 160: 1540-1543. doi:10.1164/ajrccm.160.5.9808139. PubMed: 10556117.
31. Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F et al. (2005) Interpretative strategies for lung function tests. Eur Respir J 26: 948-968. doi:10.1183/09031936.05.00035205. PubMed: 16264058. (Pubitemid 41632054)
32. Nolan CM, Goldberg SV, Buskin SE (1999) Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic. JAMA 281: 1014-1018. doi:10.1001/jama.281.11.1014. PubMed: 10086436. (Pubitemid 29143893)
33. Kunst H, Khan KS (2010) Age-related risk of hepatotoxicity in the treatment of latent tuberculosis infection: a systematic review. Int J Tuberc Lung Dis 14: 1374-1381. PubMed: 20937175.
34. Ralph AP, Yeo TW, Salome CM, Waramori G, Pontororing GJ et al. (2013) Impaired pulmonary nitric oxide bioavailability in pulmonary tuberculosis: association with disease severity and delayed mycobacterial clearance with treatment. J Infect Dis 208: 616-626. doi: 10.1093/infdis/jit248. PubMed: 23737604.
35. Kenangalem E, Waramori G, Pontororing GJ, Sandjaja S, Tjitra E et al. (2013) Tuberculosis outcomes in Papua, Indonesia: the relationship with different body mass index characteristics between Papuan and non-Papuan ethnic groups. PLOS ONE 8: e76077. doi:10.1371/journal.pone.0076077. PubMed: 24086690.
36. Ralph AP, Waramori G, Pontororing GJ, Kenangalem E, Wiguna A et al. (2013) L-arginine and Vitamin D Adjunctive Therapies in Pulmonary Tuberculosis: A Randomised, Double-Blind, Placebo-Controlled Trial. PLOS ONE 8: e70032. doi:10.1371/journal.pone.0070032. PubMed: 23967066.
37. Global Initiative for Chronic Obstructive Lung Disease (2013) Pocket Guide to COPD Diagnosis, Management and Prevention: A guide for health care professionals. Available: http://www.goldcopd.org/uploads/users/files/GOLD- Pocket-May2512.pdf. Accessed 30 September 2013
38. Karyana M, Burdarm L, Yeung S, Kenangalem E, Wariker N et al. (2008) Malaria morbidity in Papua Indonesia, an area with multidrug resistant Plasmodium vivax and Plasmodium falciparum. Malar J 7: 148. doi:10.1186/1475- 2875-7-148. PubMed: 18673572.
39. Ormerod LP, Horsfield N (1996) Frequency and type of reactions to antituberculosis drugs: observations in routine treatment. Tuber Lung Dis 77: 37-42. doi:10.1016/S0962-8479(96)90073-8. PubMed: 8733412. (Pubitemid 26066608)
40. Ruslami R, Nijland HM, Alisjahbana B, Parwati I, van Crevel R et al. (2007) Pharmacokinetics and tolerability of a higher rifampin dose versus the standard dose in pulmonary tuberculosis patients. Antimicrob Agents Chemother 51: 2546-2551. doi:10.1128/AAC.01550-06. PubMed: 17452486. (Pubitemid 47047335)
41. Casanova C, Celli BR, Barria P, Casas A, Cote C et al. (2011) The 6-min walk distance in healthy subjects: reference standards from seven countries. Eur Respir J 37: 150-156. doi:10.1183/09031936.00194909. PubMed: 20525717.
42. Miyamoto S, Nagaya N, Satoh T, Kyotani S, Sakamaki F et al. (2000) Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing. Am J Respir Crit Care Med 161: 487-492. doi:10.1164/ajrccm. 161.2.9906015. PubMed: 10673190. (Pubitemid 30129457)
43. Jones PW (2009) ST GEORGE'S RESPIRATORY QUESTIONNAIRE MANUAL. Available: http://www.healthstatus.sgul.ac.uk/SGRQ-download/SGRQ%20Manual%20June%202009. pdf. Accessed 13 March 2013
44. Ferrer M, Villasante C, Alonso J, Sobradillo V, Gabriel R et al. (2002) Interpretation of quality of life scores from the St George's Respiratory Questionnaire. Eur Respir J 19: 405-413. doi: 10.1183/09031936.02.00213202. PubMed: 11936515. (Pubitemid 34256952)
45. Erhabor GE, Adedoyin AR, Obaseki DO, Awopeju OF (2008) Evaluation of functional capacity among patients with pulmonary tuberculosis using six minute walk test [Abstract] Chest 134
46. Murray CJ, Vos T, Lozano R, Naghavi M, Flaxman AD et al. (2012) Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380: 2197-2223. doi:10.1016/S0140-6736(12)61689-4. PubMed: 23245608.
47. Burman WJ, Goldberg S, Johnson JL et al. (2006) Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis. Am J Respir Crit Care Med 174: 331-338. doi:10.1164/rccm.200603-360OC. PubMed: 16675781. (Pubitemid 44156613)
48. Diacon AH, Pym A, Grobusch M, Patientia R, Rustomjee R et al. (2009) The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med 360: 2397-2405. doi:10.1056/NEJMoa0808427. PubMed: 19494215.